5 April 2024
Publication and presentation of a Poster entitled “The beta-carboline Harmine sensitives microsatellite stable colorectal cancer mouse model to anti-PD-1 through upregulating MHC-I dependent antigen presentation machinery and improving the infiltration of CD8 T cells into the tumor microenvironment” at the AARC Annual Meeting in San Diego. The Poster is the result of joint research between AC BioScience and the Luxemburg Institute of Health.
28 February 2024
Our CEO, Andreas Schläpfer, presents our new immuno-oncology molecule ACB2112 at the 17th Annual European Life Sciences CEO Forum in Zürich
1 February 2024
Dr. Annette Ives, Ph.D., appointed Chief Scientific Officer; Breakthrough results with ACB2112 in effectively targeting the main mechanisms of immune escape and in achieving exceptional tumor growth reduction in colorectal cancer treatments in combination treatments with ICIs.
12 July 2023
Co-founder Prof. Christian Auclair resigns from his position as Director of the Board and as CSO due to health reasons. He was appointed as Honorary Director by the shareholders.
January 2023
A new molecule ACB2112 was discovered and patented, showing exceptional promise to prevent tumors from evading the immune surveillance.
November 2022
Publication of an article in Frontiers in Immunology "The Beta-carboline Harmine improves the therapeutic benefit of anti-PD1 in melanoma by increasing the MHC-1 - dependent antigen presentation" and presentation of its poster at the 3rd Immuno-Oncology Congress on 2-3 November 2022 in Copenhagen
26 August 2022
AC BioScience closes fourth Seed Round for CHF 2.5 million
AC BioScience closes fourth Seed Round for CHF 2.5 million.
AC BioScience, a Biopôle-based clinical stage biotech company, is pleased to announce the successful closure of a fourth Seed Round for CHF 2.5 million. The company (ac-bioscience.com) is pioneering the development of novel therapies in immuno-oncology and tumor vascular normalization with the first exploratory clinical trial Phase 2a for metastatic pancreatic cancer patients to start in early 2023. This bridge funding precedes a Series A Round to fund the planned clinical trials for our two lead investigational drugs.
28 March 2022
AC BioScience has been awarded Gold status by the EIT Health Investor Network
3 March 2022
Publication of an article in Cancers entitled "Is Sphingosine-1-Phosphate a Regulator of Tumor Vascular Functionality?"
3 February 2022
AC BioScience obtains Eurostars grant to accelerate the preclinical development of its immuno-stimulatory lead molecule ACB1801.
1 February 2022
Peter Hug, Ph.D., appointed to the Board of Directors
12 October 2021
AC BioScience obtains convertible loan of CHF 1.3 million.
1 September 2021
Jean-François Dufour-Lamartinie, M.D., appointed Chief Medical Officer
21 May 2021
Patent application filed for a method to enhance the efficacy of medical treatment using S1P lyase inhibitors.
16 December 2020
AC BioScience announces a License Agreement with Lexicon Pharmaceuticals Ltd. and closes third Seed Round for CHF 0.8 million.
23 September 2020
Patent application filed for immunomodulatory compounds and use thereof for the treatment and/or prevention of infectious diseases.
31 August 2020
Patent application filed for three kinase inhibitors and use thereof to mediate the loss of malignant character of tumor cells.
8 June 2020
AC BioScience presents at the International Cancer Cluster Showcase (ICCS), a satellite event to BIO 2020.
25 May 2020
AC BioScience raises CHF 1 million in second seed funding.
27 March 2020
Patent application filed for a combination of flavonoids and S1P lyase inhibitors for the treatment of lung inflammation.
15 March 2020
Patent application filed for RGD-peptide and use thereof for inhibiting RGD-binding integrins and for cancer treatment.
13 March 2020
Innosuisse approves research grant for a collaborative project with the University of Lausanne on a new therapy targeting pathogen-dependent immune subversion mechanisms for infectious diseases treatment.
7 January 2020
Collaboration Agreement signed with the Institut Gustave Roussy (IGR) for radiation therapy in combination with S1P metabolism modulators, and ACB1801 with anti PD-1 treatment, respectively.
26 August 2019
Cooperation Agreement signed with the Luxembourg Institute of Health (LIH) to determine the efficacy of combination approaches of ACB1801 with anti-PD-1 drugs.
21 August 2019
Patent application filed for various metabolites of S1P lyase inhibitors for the treatment of infectious diseases and cancer.
06 May 2019
AC BioScience presents at the Swiss Biotech Day 2019.
25 March 2019
Patent application filed for a Beta-carboline derivative (ACB1801) for the non-toxic and immunological treatment of cancer.
08 March 2019
AC BioScience raises CHF 1 million in seed funding.
November 2018
AC BioScience acquires a majority share in AC BioTech SAS in Paris.
29 May 2018
Collaborative Research Agreement signed with the University of British Columbia, Vancouver, on S1P lyase inhibitors.
26 April 2018
Innosuisse approves research grant for a collaborative project with the University of Geneva on tumor vascular normalizers (S1P).
April 2018
Collaborative Research Agreement signed with the Institut Curie, Paris; commencement of a pharmacological PDX study of NSCLC for CAP6.
24 August 2017
Conversion to a private limited stock company (Ltd.) with an increased capital of CHF 500,000; acquisition of a patent for a Peptide having the sequence SEQ.1 for use as a medicament, in particular for the treatment of cancer.
17 August 2017
Patent application filed for the enhancement of chemotherapy efficiency by Sphingosine-1-phosphate (S1P).
31 March 2017
AC BioScience established as a Limited Liability Company (LLC) at the EPFL Innovation Park.